Wendy's Board Rejects $1.4B Trian Takeover and Triggers Poison Pill Defense
SentiSense · Published · Updated
Wendy's board unanimously rejected a $1.4 billion, $7.35-per-share take-private offer from a group led by Nelson Peltz's Trian Fund Management, saying it substantially undervalues the company, and adopted a one-year poison pill. Trian, which holds about 16% of the stock, must now decide whether to raise its bid, launch a proxy fight or back the turnaround. WEN closed at $7.94, above the offer price.
WEN said on Thursday, November 5, that its board has rejected a $1.4 billion take-private proposal from an investor group led by Nelson Peltz's Trian Fund Management. The group, which also includes BlueFive Capital, Sixth Street Partners and Flynn Group, one of Wendy's largest franchisees, offered $7.35 per share in cash on October 28. A committee of independent directors formed in February concluded that the proposal "substantially undervalues" Wendy's and does not reflect the potential of its turnaround under CEO Bob Wright.
To block a hostile approach, the board adopted a shareholder rights plan, or poison pill, with a one-year duration. Wendy's said the Trian group had rejected its offer of a standstill agreement that would have paused further share purchases. Trian holds about a 16% stake and declined to comment. Its options now include sweetening the offer, staging a proxy fight or supporting the turnaround plan. The relationship runs deep: Peltz's Triarc bought Wendy's in a $2.3 billion deal in 2008, Peltz served 17 years on the board before being named chairman emeritus in 2024, and Trian executive Peter May and Bradley Peltz still sit on the board.
The rejection came alongside third-quarter results in which earnings and revenue topped Wall Street's expectations even as same-store sales declined for the seventh straight quarter. The shares, which have lost about 60% of their value over three years, closed at $7.94, up 3.8% on the day and above the $7.35 offer price, a sign the market is pricing in the possibility of a higher bid or a successful turnaround. Wendy's is not alone: Applebee's owner Dine Brands recently adopted its own poison pill against a takeover bid.
What to watch: whether Trian returns with a higher price, whether it moves toward a proxy contest given its board representation, and whether the turnaround can reverse the run of same-store sales declines. With the stock trading above the offer, the bar for any revised bid has effectively moved higher.
Related Stocks
Powered by SentiSense - Intelligent Market Analysis